Feed RNXT
RN

RenovoRx, Inc.

RNXT · NASDAQ

$1.69 -3.43% (-$0.06)
1M +46.67%
Market Cap $76.1M
P/E Ratio -
Div. Yield -
ROE 145.63%

Bulios Fair Price

$1.56

7.7% downside

Trenutna cena

$1.69

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica RNXT trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/S 38.53x
P/B 8.48x
P/E N/A
Growth
4 /100
Declining
Book val. growth 4.18%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak
Gross margin 84.41%
Net margin 621.71%
Op. margin 678.04%
Quality
2 /100
Poor
ROIC 139.74%
ROE 145.63%
ROA 107.09%
Debt
100 /100
Low
Debt/Equity 0.03x
Current ratio 5.74x
Int. coverage N/A
Stability
76 /100
Stable
Beta 0.99x
EPS volatility 9.48%
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o RNXT
Online

O podjetju

RenovoRx, Inc. (RNXT) is an American biotechnology company focused on developing innovative therapies for the treatment of hard-to-treat cancers. The company is developing advanced targeted treatment technologies that enable the direct delivery of chemotherapy to tumors with minimal impact on surrounding healthy tissues. The company's flagship product is the RenovoTAMP™ system, designed to improve the efficacy and reduce the side effects of cancer treatment. RenovoRx aims to provide new treatment options for patients with limited therapeutic alternatives. RenovoRx, Inc. (RNXT) shares could be an interesting choice for investors looking for opportunities in the biotechnology sector and innovative treatment technologies.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Shaun R. Bagai

Employees

17

Headquarters

Mountain View

Prihajajoči dogodki

12 NOV.

Earnings

Upcoming earnings report

58d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.